Altimmune Inc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
ALT$1.94-8.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
6. Accrued Expenses and Other Current Liabilities
- Accrued Expenses and Other Current Liabilities
Accrued expense and other current liabilities consist of the following (in thousands):
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, | ||||||
| · · 2023 · · 2022 | ||||||
| Accrued professional services | $293 | $276 | ||||
| Accrued payroll and employee benefits | | 3,315 | | 2,955 | ||
| Accrued research and development | | 5,845 | | 7,295 | ||
| Lease obligation, current portion (see Note 5) | | 496 | | 452 | ||
| Excess tax refund payable | | | — | | | 1,169 |
| Accrued interest and other | | 124 | | 103 | ||
| Total accrued expenses and other current liabilities | | $10,073 | | $12,250 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.